From our latest Research Update Newsletter:
Epratuzumab is an investigational agent for the treatment of lupus. It is an antibody that binds to a protein called CD22 on B cells, which are white blood cells known to be hyperactive in many people with lupus. The researchers hoped to learn whether epratuzumab could be a safe and effective treatment for people with moderate-to-severe lupus. They also wanted to find the best way to give the treatment (which dose and how often to give it) to get the best possible effects.
Read more >>
Want to read these summaries earlier? Sign up for our newsletters here.
Subscribe to:
Post Comments (Atom)
1 comment:
Epratuzumab is in two Phase III pivotal trials.
http://www.clinicaltrials.gov/ct2/show/NCT01262365?term=epratuzumab&recr=Open&phase=2&rank=1
http://www.clinicaltrials.gov/ct2/show/NCT01261793?term=epratuzumab&recr=Open&phase=2&rank=2
Post a Comment